Videos

Erika P. Hamilton, MD, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

Daneng Li, MD, discusses potential second-line options following treatment with bevacizumab plus atezolizumab in patients with hepatocellular carcinoma.

Valencia D. Thomas, MD, MHCM, discusses the unmet needs which remain in the non-melanoma skin cancer space.

Sumanta K. Pal, MD, discusses the safety and efficacy results of the COSMIC-021 clinical trial.

Giuseppe Fallaro, MD, discusses research comparing baseline characteristics of patients with renal cell carcinoma treated with adjuvant pembrolizumab in the real-world setting compared with those treatment treated in the KEYNOTE-564.

Srdan Verstovsek, MD, PhD, discusses why the first ever FDA approved interferon drug ropeginterferon alfa-2b-njft is important for adult patients with polycythemia vera.

Nicolas Gazeau, MS, discusses next steps and unmet needs following a positive retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who received chimeric antigen receptor T-cell therapy.

Karen L. Reckamp, MD, discusses the key findings of the phase 2 Lung-MAP substudy S1800A for patients with stage IV, previously-treated non–small cell lung cancer.

Dr. Marc Matrana closes the discussion with considerations for clinicians on treating patients with prostate cancer.

Insight on recent developments and emerging options in the mCSPC treatment landscape.

An experienced clinician expands on effective strategies for monitoring patients with mCSPC during and after treatment and reviews patient expectations following disease progression.

Discussion centered around androgen receptor inhibition/androgen synthesis inhibition and comparison of available, approved options for each.

Christopher J. Melani, MD, discusses the results of a trial investigating a combination regimen in a cohort of patients with mantle cell lymphoma.

Clinical insights concerning the selection of effective treatment approaches for patients with mCSPC with comments on the study design and results of the TITAN study.

A prostate cancer expert shares a brief overview of available first-line therapy options for patients with mCSPC.

Marc Matrana, MD shares his perspective on an mCSPC patient case, focusing on the typical trajectory for patients with biochemical recurrence.

Jeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.

William J. Gradishar, MD, discusses the most recent evolutions in the management of patients with advanced breast cancer.

Dr Nizar Tannir compares data among the 4 approved first-line I/O combination therapy regimens in advanced clear cell RCC.

Nizar Tannir, MD, provides an overview of the method of risk stratification for advanced RCC and the NCCN Guidelines for treatment based on risk group.

Heinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.

Ian W. Flinn, MD, PhD, discusses his experience using the combination of polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

Kashyap Patel, MD, discusses the current disparities in the myeloma space and the ways in which oncologists are handling them.

Daniel J. George, MD, discusses why he considers using prostate-specific membrane antigen imaging early in treatment of patients with castration-resistant prostate cancer.

Cary Gross, MD, discusses the key takeaways from his retrospective research examining patients with advanced non–small cell lung cancer and its association with Medicaid insurance, rates of biomarker testing, and patient outcomes.

Peter A. McSweeney, MD, discusses challenges with implementing chimeric antigen receptorT-cell therapy in some community oncology practices.

Charles J. Schneider, MD, FACP, discusses the ways in which the management and care of patients with anal carcinoma has changed over the past decade.

Wesley Burkett, MD, discusses treatment options for endometrial cancer.

Brandon Sheffield, MD, explains the biomarkers that are important to identify before treating a patient who has been diagnosed with non–small cell lung cancer.

Pedro C. Barata, MD, MSc, discusses treatment options for patients with non–clear cell renal cell carcinoma.